



Hyponatraemia and hypernatraemia: Disorders of Water Balance in Neurosurgery

Mendel Castle-Kirszbaum¹ · Mervyn Kyi² · Christopher Wright³ · Tony Goldschlager^{1,4} · R. Andrew Danks^{1,4} · W. Geoffrey Parkin^{4,5}

Received: 10 August 2020 / Revised: 26 September 2020 / Accepted: 25 November 2020
© The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021

Abstract

Disorders of tonicity, hyponatraemia and hypernatraemia, are common in neurosurgical patients. Tonicity is sensed by the circumventricular organs while the volume state is sensed by the kidney and peripheral baroreceptors; these two signals are integrated in the hypothalamus. Volume is maintained through the renin-angiotensin-aldosterone axis, while tonicity is defended by arginine vasopressin (antidiuretic hormone) and the thirst response. Edelman found that plasma sodium is dependent on the exchangeable sodium, potassium and free-water in the body. Thus, changes in tonicity must be due to disproportionate flux of these species in and out of the body. Sodium concentration may be measured by flame photometry and indirect, or direct, ion-sensitive electrodes. Only the latter method is not affected by changes in plasma composition. Classification of hyponatraemia by the volume state is imprecise. We compare the tonicity of the urine, given by the sodium potassium sum, to that of the plasma to determine the renal response to the dysnatraemia. We may then assess the activity of the renin-angiotensin-aldosterone axis using urinary sodium and fractional excretion of sodium, urate or urea. Together, with clinical context, these help us determine the aetiology of the dysnatraemia. Symptomatic individuals and those with intracranial catastrophes require prompt treatment and vigilant monitoring. Otherwise, in the absence of hypovolaemia, free-water restriction and correction of any reversible causes should be the mainstay of treatment for hyponatraemia. Hypernatraemia should be corrected with free-water, and concurrent disorders of volume should be addressed. Monitoring for overcorrection of hyponatraemia is necessary to avoid osmotic demyelination.

Keywords Hyponatraemia · Hypernatraemia · SIADH · Cerebral salt wasting · Diuretics · Diabetes insipidus

Introduction

Disorders of water balance (“dysnatraemias”) are common. In addition to substantial economic and resource burdens [18], dysnatraemias are a preventable cause of secondary brain

injury and can worsen outcome and increase mortality [9]. Individuals with a plasma sodium concentration ($[Na^+]_p$) < 130 mmol/L have a mortality rate 59-fold (11.2% vs 0.19%) that of normonatremic individuals. The severity of the hyponatraemia also correlates with mortality; those with a $[Na^+]_p$ < 120 mmol/L have greater than 2.5-fold the mortality (25% vs 9.3%) of those with a $[Na^+]_p$ between 120 and 130 mmol/L. Hyponatraemia in individuals with subarachnoid haemorrhage (SAH) is associated with increased rates of delayed cerebral ischemia (DCI) [52, 140] and worse outcome [106], while severe hypernatraemia ($[Na^+]_p$ > 160 mmol/L) is an independent predictor of poor outcome in general neurosurgical patients [6].

Physiology of sodium and water balance

Disorders of volume, hypervolaemia (oedema) and hypovolaemia, are disorders of sodium balance. Disorders of

✉ Mendel Castle-Kirszbaum
mdck.journal@gmail.com

¹ Department of Neurosurgery, Monash Health, Melbourne, Australia

² Department of Endocrinology, Melbourne Health, Melbourne, Australia

³ Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia

⁴ Department of Surgery, Monash University, Melbourne, Australia

⁵ Department of Intensive Care, Monash Health, Melbourne, Australia



SHOUT
SHARE IT

water balance, hyponatraemia (water overload) and hypernatraemia (water depletion), may occur independently or coexist with disorders of volume.

Osmoles are a measure of solute within a solution and may be described by osmolarity (solute per unit volume) or osmolality (solute per unit weight). Tonicity is the summed strength of the effective osmoles, that is, osmoles that cannot easily cross cellular membranes and thus influence water distribution. Ineffective osmoles include urea, alcohols (ethanol, methanol, ethylene glycol) and acetone; these substances can confound laboratory results and they contribute to measured plasma osmolarity without influencing the distribution of water [109]. Tonicity, not osmolarity, is the key to water balance.

The body is a reservoir that exquisitely balances influx and efflux of free-water and solute (Fig. 1). Even with maximal urine concentration (~1200mosm/L), approximately 500 ml/day of free-water is required to excrete the approximately 10 mosm/kg/day of waste solute. Conversely, if effective osmole intake is low compared to water intake, even maximal urinary dilution (50–100 mosl/L) can be insufficient to excrete ingested water. Exceptionally, urea can be excreted in nonlinear fashion to facilitate constant nitrogen balance despite varying water [44]:

$$\text{Urine Volume} = \frac{\text{Solute}}{\text{Urine Concentration}}$$




Fig. 1 Summary of the daily flux of free-water in an average individual. Each flux may be obligatory (unregulated) or regulated. Influx of free-water and solute is mostly dietary (obligatory) and metabolic (water liberated from oxidation of carbohydrates), while regulated intake of water also occurs via the thirst response and hedonistic/social intake. Obligatory water excretion occurs through “insensible losses” (trans-epidermal diffusion, sweat, airway humidification and gastrointestinal output; totaling approximately 10–12 ml/kg/day) and that required to eliminate excess

Regulation of plasma tonicity is achieved by alterations in water balance through the central arginine vasopressin (AVP, antidiuretic hormone) axis, while regulation of plasma volume is through the renal renin-angiotensin-aldosterone (RAA) axis. RAA activity leads to retention of volume (solute and solvent together) and is independent of changes in tonicity when intravascular haemodynamics are normal (Fig. 2).

The organum vasculosum of the lamina terminalis (OVLT) is the primary tonicity-receptor, though other circumventricular organs (devoid of a blood-brain barrier) as well as the median preoptic nucleus (MPN) and magnocellular neurons of the neurohypophysis itself are intrinsically tonicity-sensitive. At these regions converge other regulators of AVP release, including angiotensin II which activates neurons of the subforniceal organ, OVLT and MPN. In response to an increase in plasma tonicity or angiotensin II release due to hypovolaemia, projections from the circumventricular organs to the MPN activate the magnocellular neurons of the neurohypophysis. Converging on these magnocellular neurons are projections from the nucleus tractus solitarius and ventrolateral medulla which relay baroreceptor signals. Thus, tonicity and volume signals integrate at the site of AVP release, the magnocellular neurons of the neurohypophysis. AVP acts on the kidney to stimulate free-water resorption, thus concentrating urine. AVP also upregulates urea transport proteins in the collecting duct, improving the concentrating capacity of the medullary loops.

AVP is secreted when tonicity increases above an individual’s osmostat set point, generally 280–285mosm/kg,

solute and metabolic waste through the kidney. The water content of food varies with diet while the regulated water intake varies with societal norms, diet and thirst. Transdermal and respiratory evaporative losses may vary with environmental temperature and activity, while regulated renal losses relate to regulated water intake. Patients inhaling prehumidified air, such as those receiving mechanical ventilation, high-flow nasal cannulae or pressure support, will have reduced respiratory losses




Fig. 2 Summary of water and volume homeostasis. AVP is the primary mediator of tonicity regulation, controlled by tonicity receptors and volume signalling. Negative feedback is shown in red (broken) lines. The thirst response and free water absorption in the collecting duct

(V2 receptor mediated) lead to reduction in plasma tonicity. Sodium retention, mediated by aldosterone and decreased ANP, increases the volume state. ANP, atrial natriuretic peptide; AVP, arginine vasopressin (antidiuretic hormone); RAA, renin angiotensin aldosterone

although significant interindividual variability is seen [109, 110, 117]. Moreover, the set point may drift, often to become more sensitive, with age, pregnancy, medications and fluctuations in serum ionized calcium [69, 77, 142]. The circumventricular organs are exquisitely sensitive to changes in tonicity; perturbations as small as 1% cause changes in AVP release. The tonicity at which healthy adults first report a conscious desire to drink (thirst threshold) is the same as, or a few milliosmoles greater than, the osmostat set point [59, 132]. In those with primary polydipsia, the thirst threshold is much lower than this osmostat set point.

Maximal free-water resorption is reached at approximately 294 mosm/Kg, corresponding to an AVP concentration of approximately 5 pg/ml [109]. Further increases in tonicity lead to further AVP release, although concentrating activity is maximal, to bolster the thirst mechanism. As a result, hypernatraemia will almost only occur in the setting of an impaired thirst mechanism, damage to the neurohypophysis or inadequate access to free-water.

The volume state interacts with AVP secretion in two ways: Firstly, independent of changes to tonicity, a marked decrease (≥ 8 –10%) in the volume state stimulates AVP release. Secondly, changes to the volume state alter the set point

and gain of the AVP response to tonicity. Hypovolaemia leads to more AVP secretion for a given tonicity and shifts the threshold for secretion to a lower tonicity (Fig. 3). Although the threshold for hypovolaemia stimulating AVP release is much greater than for tonicity, the AVP response to volume depletion is exponential and stronger, though diminishes with age [69].

The Edelman equation

In 1958, Edelman demonstrated that $[Na^+]_p$ is related to the total exchangeable sodium (Na^+_e), total exchangeable potassium (K^+_e) and total body water (TBW) (Fig. 4) [35, 100]:

$$[Na^+]_p = 1.11 \cdot \frac{Na^+_e + K^+_e}{TBW} - 25.6$$

For simplicity, however, the Edelman equation can be reduced to:

$$[Na^+]_p \propto \frac{Na^+_e + K^+_e}{TBW}$$




Fig. 3 Relationship between AVP, thirst and plasma osmolality is modified by the volume state. Increasing degrees of hypovolaemia shift the threshold for thirst and AVP release to lower osmolalities. The gain is also increased by hypovolaemia, with more AVP secreted per unit increase in osmolality. AVP, arginine vasopressin (antidiuretic hormone)

Thus, the main effective osmoles in the body, sodium and potassium, determine the $[Na^+]_p$. From this, we extrapolate that perturbations in $[Na^+]_p$ are due to altered flux of effective osmoles and free-water in and out of the body. Conversely,

ineffective osmoles do not have any effect on $[Na^+]_p$. Urea contributes to osmolality but not tonicity:

$$Osmolality_{Calculated} = 2 \cdot ([Na^+]_p + [K^+]_p) + [Glucose]_p + [Urea]_p$$

Other effective osmoles (besides sodium and potassium) affect $[Na^+]_p$. In health, plasma glucose is tightly controlled between 4 and 11 mmol/L. However, the neurosurgical peri-operative period is often not healthful; patients with acromegaly and Cushing's disease are prone to hyperglycaemia, as are those on perioperative steroids. At higher concentrations, glucose, mannitol and other effective osmoles cause a shift of TBW into the ECF, reducing $[Na^+]_p$. This translocational hyponatraemia is physiologically necessary to maintain normal plasma tonicity. Translocation has been quantified as a 1 mEq/L drop in $[Na^+]_p$ for every 3.5 mmol/L increase in $[glucose]_p$ above normal (6.7 mmol/L). Correction of $[Na^+]_p$ for $[Glucose]_p$ separates this translocational effect from concurrent disorders of water balance. A large discrepancy (e.g. > 10 mmol/L) between calculated and measured osmolality suggests an unmeasured osmole is present. Translocational hyponatraemia (hyperosmolar hypertonic hyponatraemia) occurs with high levels of glucose, mannitol and contrast agents,

$$[Na^+]_p = \frac{G}{\phi} \cdot \left(\frac{Na^+_e + K^+_e}{TBW} \right) - \frac{G}{\phi} \cdot \left(\frac{Na^+_{inactive} + K^+_{inactive}}{TBW} \right) - \frac{Osmol_{ICF} + Osmol_{ECF}}{TBW} + [K^+]_p + \frac{Osmol_{pw}}{V_{pw}}$$

$$[Na^+]_p = 1.11 \cdot \frac{Na^+_e + K^+_e}{TBW} - 25.6$$

$$G = \frac{V_{pw} + V_{ISF}}{V_{pw} + 0.95 \cdot V_{ECF}} \approx 1.04$$

$$\phi \approx 0.94$$

$$\frac{G}{\phi} \approx \frac{1.04}{0.94} \approx 1.11$$

Osmotically inactive electrolytes: Skin, Bone

Other osmotically active compounds: Glucose, Protein

Fig. 4 The Edelman and Nguyen-Kurtz equations. The Edelman equation (top) and its corresponding coefficients in the Nguyen-Kurtz equation (bottom). The gradient (1.11) is the ratio of the coefficient of the Gibbs-Donnan effect (GDE) ($G = 1.04$) and the average osmotic coefficient of sodium salts ($\phi = 0.93-0.94$). The GDE is due to the higher concentration of large, anionic plasma proteins intravascularly that cannot cross the endothelium/glycocalyx barrier, thus attracting further sodium cations to the vascular space to balance their electromagnetic charge. The Y-intercept is related to the other osmotically effective species in the ICF ($Osmol_{ICF}$), ECF ($Osmol_{ECF}$) and plasma water ($Osmol_{pw}$); the plasma water volume (V_{pw}) and potassium concentration ($[K^+]_p$); and the

inactive/bound sodium ($Na^+_{inactive}$) and potassium salts ($K^+_{inactive}$). The components of the Nguyen-Kurtz equation that represent osmotically inactive stores of exchangeable sodium and potassium (such as stored in the skin, interstitial spaces and bone) as well as the other osmotically active components of plasma (glucose and plasma proteins) are shown in dotted boxes. Several important lessons can be gleaned from these equations. Firstly, the main effective osmoles in the body, sodium and potassium determine the $[Na^+]_p$. From this, we extrapolate that perturbations in $[Na^+]_p$ are due to altered flux of effective osmoles and free-water in and out of the body. Secondly, ineffective osmoles do not have any effect on $[Na^+]_p$. Urea contributes to osmolality but not tonicity

and removal of the osmole will generally ameliorate the hyponatraemia. Conversely, with high levels of ineffective osmoles (urea, alcohols), a hyperosmolar hypotonic hyponatraemia can develop. In this latter situation, the cause of the hyponatraemia still requires investigation as usual.

Neurosurgical and neurological dysnatraemias

Syndrome of inappropriate antidiuresis

The syndrome of inappropriate antidiuresis describes AVP secretion inappropriate from the plasma tonicity and intravascular volume state. SIAD is a diagnosis of exclusion but should be considered when known precipitants of SIAD are present (Fig. 5) [125, 136]. High levels of AVP increase free-water resorption in the collecting duct, thus increasing TBW leading to plasma dilution and ECF volume expansion. The expansion of the ECF leads to a pressure natriuresis which restores the normal ECF volume but leads to effective osmole loss that worsens the hyponatraemia. Given the RAA axis is unimpaired, and thus renal salt handling is intact, euvolemia is the norm.

AVP may be secreted inappropriately in response to cerebral pathology [74]. Classically, these are associated with AVP in the high normal range but not responsive to changes in tonicity. This is in contrast to grossly elevated AVP levels, typical for ectopic secretion from neuroendocrine tumours [39].

Anti-epileptics, namely, carbamazepine and its derivative oxcarbazepine, may cause a syndrome similar to SIAD, due to increased renal sensitivity to AVP and possibly a shift of the osmostat “set point” [135]. Hyponatraemia occurs in 26% of those taking carbamazepine and 46% on oxcarbazepine [15]. It is especially common in elderly patients [60], is dose dependent [85] and is more likely in those with a history of hyponatraemia and on concomitant diuretics.

Cerebral-renal salt wasting

Intracerebral catastrophes may be associated with ECF depletion, high urine sodium losses, hypovolaemia and an ensuing hyponatraemia. Traditionally termed cerebral salt wasting syndrome, we prefer this association to be termed cerebral-renal salt wasting (CRSW) [88]. Classically described in SAH [64, 139], it has been described in other neurosurgical diseases including TBI [71, 86], aneurysm clipping [98], vault reconstruction for craniosynostosis [45, 75] and infection [123]. CRSW has been variably attributed to natriuretic peptide release, alterations of sympathetic outflow to the kidney which downregulate the RAA axis and directly impair proximal tubular sodium resorption, and hypothalamic-pituitary-adrenal

axis dysfunction (Fig. 6) [103]. The differentiation of CRSW and SIAD, and even the concept of CRSW itself, has been the subject of much debate. As the ECF is depleted in the early stages of CRSW, baroreceptor signalling causes increased secretion of AVP, leading to hyponatraemia. Urinary sodium concentration (which is often a critical step in differentiating the aetiology of hyponatraemia) is not helpful in differentiating between CRSW and SIAD. The only clinical difference is the ECF status (deplete in CRSW and replete in SIAD), which is often difficult to measure clinically [25, 93]. Neurosurgical studies utilizing (gold standard) radioisotope dilution methods demonstrate that there is a subset of hyponatremic patients with depleted ECF better explained by CRSW than SIAD [98, 139].

Central diabetes insipidus

Diabetes insipidus (DI) is caused by interruption of the AVP axis leading to inappropriate free-water excretion and hypernatraemia. Central DI is the most common type and most relevant to neurosurgical patients, often seen after sellar surgery or head trauma. Damage to 80–90% of hypothalamic magnocellular neurons is necessary before symptoms arise [54]; transient DI and permanent DI are seen after 10–20% and 2% of pituitary surgeries, respectively [55, 99]. The risk of DI after surgery increases with intraoperative CSF leak; specific pathologies include craniopharyngioma, Rathke cleft cysts, and Cushing’s disease; young age; extrasellar expansion; and the extent of superior resection [55, 79, 99]. Sectioning above the median eminence generally causes permanent DI, as the probability of Wallerian degeneration of the magnocellular neuron is proportional to the proximity of the axotomy from the soma (located in hypothalamic nuclei). More superior damage to the circumventricular organs, specifically the SFO and OVLT, such as after anterior communicating artery aneurysm (AComA) clipping and craniopharyngioma resection [28], may lead to central DI with adipisia [133].

Occult AVP deficiency may be masked by concurrent ACTH deficiency and only after glucocorticoid replacement therapy has been administered do the symptoms DI appear. Firstly, cortisol induces resistance of the V_2 receptor (or at a post-receptor level) to AVP; thus in states of glucocorticoid deficiency, the effects of AVP are amplified [118]. Secondly, corticotrophin-releasing hormone (CRH) stimulates ACTH and AVP release; as glucocorticoid deficiency upregulates CRH, thus AVP release is increased [23]. Lastly, hypocortisolaemia results in renal sodium loss and volume depletion, potent stimulators for increased (but “appropriate”) AVP release. As such, when glucocorticoid deficiency is ameliorated, these compensatory mechanisms fail, and DI ensues. Thus, assessment of AVP function both before and after





Fig. 5 Common causes of the syndrome of inappropriate antidiuresis. Typical duration of SIAD caused by each aetiology is shown in grey. AIDS, acquired immunodeficiency syndrome; AVP, arginine vasopressin (antidiuretic hormone); CVST, cerebral venous sinus thrombosis; GIT, gastrointestinal tract; GUT, genitourinary tract; MAOIs, monoamine oxidase inhibitors; MDMA, 3,4-methylenedioxy

methamphetamine; SAH, subarachnoid haemorrhage; SCLC, small cell lung carcinoma; SDH, subdural hematoma; SIAD, syndrome of inappropriate antidiuresis; SNRI, serotonin noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TBI, traumatic brain injury; TCA, tricyclic antidepressant

Fig. 6 Pathophysiology of the cerebral-renal salt wasting after intracranial catastrophe. CRSW has been variably attributed to natriuretic peptide release, alterations of sympathetic outflow to the kidney which downregulates the RAA axis and directly impairs proximal tubular sodium resorption, and hypothalamic-pituitary-adrenal axis dysfunction. This culminates in ECF depletion, and consequent baroreceptor signalling causes increased secretion of AVP, leading to hyponatraemia. ACTH, adrenal corticotrophic hormone; PCT, proximal convoluted tubule; SNS, sympathetic nervous system



glucocorticoid replacement appears to increase the sensitivity for diagnosis of DI [19].

Central DI is a rare presenting feature of pituitary adenomas and other slow-growing lesions of the sella. As AVP synthesis occurs in the hypothalamus and not the neurohypophysis, slow destruction of the latter damages only the magnocellular nerve terminals, allowing the site of secretion to migrate superiorly to the stalk or hypothalamus [24]. Given the substantial reserve of magnocellular neurons, sellar lesions causing DI are often fast growing and highly destructive, such as metastases, carcinoma or apoplexy. It should also be noted that conditions affecting stalk (e.g. Langerhans cell histiocytosis, sarcoidosis and autoimmune hypophysitis) may cause DI early in their course.

In a patient with new central DI, MR imaging of the sellar region is paramount to exclude a structural lesion in the absence of trauma or surgery. Idiopathic central DI is a diagnosis of exclusion in the setting of a normal MRI and is likely autoimmune [24]. MRI may demonstrate absence of the posterior pituitary bright spot, but this is not specific [26]. Anti-vasopressin cell antibodies are present in the majority of cases [89], while DI associated with adipsia is seen with auto-antibodies to the circumventricular organs [57]. The presence of a thickened pituitary stalk ($> 2\text{--}3\text{ mm}$) is generally pathological, and the combination of a thickened stalk and absent bright spot demands thorough investigation for neoplastic and infiltrative lesions of the hypothalamus and pituitary [24].

Dysnatraemias following pituitary surgery

Given the proximity of tonicity receptors and magnocellular neurons to the adenohypophysis, dysnatraemias are relatively common after sellar surgery. Dysnatraemias also represent the most common cause for delayed unplanned re-admission following pituitary surgery, accounting for 70% of cases [17]. Risk factors for dysnatraemias after pituitary surgery include male gender, younger age, larger tumours (macroadenomas), greater extent of resection, suprasellar extension, reoperation, CSF leak, non-adenoma lesions (Rathke's cleft cyst and craniopharyngioma), Cushing's disease, and microscopic (c.f. endoscopic) approaches [7, 27, 80, 99, 116, 141]. The initiation of DI may be delayed after Rathke's cleft cyst surgery, as the cyst contents incite sterile inflammation of the stalk which may present weeks to months postoperatively [53]. Furthermore, those with surgically managed Cushing's disease are at increased risk of fluctuating serum sodium due to the opposing effects of relative glucocorticoid deficiency and central DI; indeed up to 70% exhibit some abnormality in sodium and water balance postoperatively [55].

Post-traumatic and post-surgical patients may exhibit fluctuations in AVP secretion termed "biphasic" and "triphasic" responses (Fig. 7). Immediately after surgery, DI may develop due to interruption of axons and axoplasmic flow in the

magnocellular osmoregulatory system. This may arise from surgical manipulation of the stalk or neurohypophysis, or excision [121]. An increase in serum sodium of 4.5 mmol/L from preoperative to first postoperative testing is 91% specific and has a positive predictive value of 57% for DI, while a postoperative serum sodium of $> 145\text{ mmol/L}$ is 98% specific [116]. After some time, generally 5–7 days, stored AVP may be released from Herring bodies of the neurons distal to the site of axonal injury leading to a transient SIAD. Finally, after partial damage to magnocellular neurons, the remaining neurons and regenerating axons begin to secrete AVP, and normal osmoregulation reinstated (biphasic response). However, if damage is severe, all magnocellular cells may degenerate, and once AVP stores are exhausted, chronic DI persists (triphasic response).

Hyponatraemia following pituitary surgery is usually SIAD [29]. It is generally delayed, with a nadir 7–9 days postoperatively [113, 114], and is associated with larger tumours, younger age and reoperation [126]. This SIAD likely represents an "isolated second phase" of the triphasic response. Initial trauma to the stalk is incomplete, with persisting neurons sufficient to defend plasma tonicity. However, degeneration of damaged neurons continues, and delayed release of stored AVP produces a transient SIAD. Once these stores are exhausted, the remaining neurons again resume to maintain normal tonicity [105].

Dysnatraemias following SAH

Hyponatraemia following SAH is common, occurring in up to 56% of patients [50, 122]. Risk factors include increased age, aneurysmal aetiology [122], current smoking [119], AComA aneurysms [115], post-SAH hydrocephalus, rebleeding [84], high SAH grade, large clot volume [90] and surgical or endovascular intervention. Generally, SIAD is considered more common than CRSW, but this is contentious [122]; both have a similar morbidity and mortality [64]. Atrial, brain and dendroaspis [65] natriuretic peptides are increased after SAH [14, 36, 61, 63, 130, 134], are associated with hypovolaemia [33] but may not specifically cause hyponatraemia [50, 130]. Aldosterone levels are generally suppressed despite normal renin levels [14]. AVP (and a by-product of its formation, copeptin) levels are greater in patients with DCI independent of plasma tonicity [41]. Total glucocorticoid levels are commonly low after SAH [66, 67, 104]. However, as cortisol is highly protein bound, simultaneous "negative acute-phase" changes in carrier protein concentration may dictate that free cortisol levels are actually normal [47, 68]. Concentrations of albumin and corticosteroid-binding globulin should be considered before renal salt wasting is attributed to glucocorticoid deficiency. Importantly, hypervolaemic hyponatraemia and hyponatraemia due to inappropriate fluid replacement are also seen after SAH [50, 122]. The severity of the hyponatraemia




Fig. 7 Pathophysiology of the triple response to magnocellular injury after pituitary surgery. Immediately after surgery DI may develop due to interrupted axoplasmic flow in the magnocellular neurons. After a variable amount of time, generally 5–7 days, AVP stored in Herring bodies located at the terminal part of the magnocellular axon is released, leading to a transient SIAD. Once the AVP stores are exhausted,

degeneration of the damaged neurons leads to chronic DI. When damage is less severe, the spared neurons are sufficient to defend body tonicity, but unregulated release of stored AVP in the affected neurons still causes a transient SIAD around days 5–9 (isolated second phase). *SON* supraoptic nucleus; *PVN*, paraventricular nucleus; *AVP*, arginine vasopressin

and its trajectory are independent risk factors for poor outcome after SAH [34, 91], length of hospital stay [91, 122] and the development of DCI [34]; however, the overall impact of hyponatraemia on outcome is small [106, 138].

DI is uncommon after SAH [106, 131]. It is generally transient but may persist in some patients [5]. DI is associated with AComA aneurysms and is particularly important to recognize and treat given the risk of DCI with hypovolaemia. Adipsic DI may complicate surgical clipping of AComA aneurysms [124].

Dysnatraemias following traumatic brain injury

Hyponatraemia commonly complicates traumatic brain injury (TBI), occurring in approximately 13% of cases [108], and is associated with longer hospital stays and poorer outcome [95]. The incidence correlates with radiological severity [82], the majority of cases are due to SIAD [3] and complete recovery is the norm [4]. CRSW may also complicate TBI, with an incidence of 0.8–34.6% [73], greater in those with more

severe injury. Late-onset hyponatraemia, in the second week post-injury, tends to resemble CRSW more than SIAD [51]. Although uncommonly the sole cause for hyponatraemia, concomitant hypothalamic-pituitary-adrenal axis dysfunction may complicate post-TBI hyponatraemia [49].

The frequency of DI following TBI correlates with clinical and imaging severity, occurs in over 20% of individuals acutely and persists in approximately one-quarter of these cases [3]. Initially, oedema, ischemia or direct neuronal injury to the hypothalamus and stalk causes DI that presents within 2–3 days of injury [2], correlating with maximal post-traumatic oedema. Resolution of oedema leads to resolution of DI in the majority; however, with direct injury to magnocellular neurons, DI may present earlier and be permanent. Concomitant injury to the thirst centres leads to adipsic DI, which carries a worse prognosis [124]. The presentation of post-traumatic DI may be delayed and may occur in the absence of acute-phase DI. All individuals with resolved post-traumatic acute DI should have a screening post-acute phase water deprivation test, while those without a history of acute post-traumatic DI

that are asymptomatic (no ongoing thirst, polyuria or nocturia) and have normal urine output (<3 L/day) require no further assessment [3].

Common “medical” dysnatraemias

The reset osmostat

The reset osmostat, common in pregnancy, is a shift of the osmostat set point where AVP secretion begins to increase significantly [10]. The diagnosis should be considered in those with mild hyponatraemia or hypernatraemia that is stable over long time periods despite varying solute and water intake. Importantly, AVP secretion will alter appropriately after water and salt loads to maintain tonicity at this new set point.

Hypovolaemic hyponatraemia

Intravascular hypovolaemia is a potent stimulus for AVP secretion. As such, free-water is retained in states of whole-body salt and water depletion (hypovolaemia). This is not SIAD; secretion will normalize when intravascular haemodynamics are restored.

Diuretic-induced hyponatraemia

Thiazides are the primary offender in diuretic-associated hyponatraemia [56]. Thiazides impair diluting ability of the nephron, stimulate AVP release and increase water resorption in the inner medullary collecting duct independent of AVP [20]. The combination of water retention and renal salt wasting begets hyponatraemia. Because thiazides impair urinary dilution, those that require maximally dilute urine to maintain water balance (e.g. those with poor solute intake, psychogenic polydipsia or “beer potomania”) are especially vulnerable. Discontinuation of thiazides may lead to dangerously prompt correction of serum sodium, with the risk of osmotic demyelination augmented by the concurrent hypokalaemia induced by thiazides.

Loop diuretics (e.g. frusemide), although more prevalent than thiazides in hospitalized patients with hyponatraemia [46], seldom cause hyponatraemia themselves. They disrupt the countercurrent concentrating mechanism of the nephron and lead to an increase in free-water clearance. Hypovolaemia-induced hyponatraemia from overzealous loop diuresis is possible, but uncommon. More commonly, patients with another cause for their hyponatraemia, such as heart failure or renal failure, are also on a loop diuretic, and the latter is wrongly ceased. Potassium-sparing diuretics (e.g. spironolactone) do mildly reduce serum sodium [21] but are unlikely to cause hyponatraemia in isolation.

Hypervolaemic hyponatraemia

In states of whole-body hypervolaemia, but reduced effective intravascular volume, such as heart failure or cirrhosis, intravascular depletion stimulates AVP release and thus hyponatraemia. Normalization of intravascular dynamics may improve hyponatraemia, although hyponatraemia is an independent risk factor for mortality in these patients [16, 70, 72, 112].

Sodium measurement and pseudohyponatraemia

Methods of measuring $[\text{Na}^+]_p$ include flame photometry (FP); the indirect ion-sensitive electrode (I-ISE), used for “formal” pathology tests; and the direct ISE (D-ISE), used in point-of-care analysers [76] (Table 1). FP and I-ISE may produce spurious results in the setting of elevated or decreased plasma solid phase, termed pseudohyponatraemia and pseudohypernatraemia, respectively. The D-ISE is not influenced by the solid phase composition of plasma [30, 32, 42, 129] (Fig. 8).

A physiology based approach to dysnatraemia

Traditionally, dysnatraemias were classified by the apparent volume state of the individual. The clinical utility of such a classification is hampered by the difficulty of accurately measuring the volume state [25, 92]. Indeed, clinicians perform worse than the flip of a coin in differentiating between hypovolaemia and euvolemia in individuals with hyponatraemia [6]. Our approach to dysnatraemia is centred around the flux of effective osmoles and water entering and exiting the body. Simply, if more effective osmoles are excreted than ingested, or more free-water is gained than lost, $[\text{Na}^+]_p$ will fall. Conversely, if more effective osmoles are ingested than excreted, or more free-water is lost than gained, $[\text{Na}^+]_p$ will rise. As such, we have categorized the common causes of hyponatraemia and hypernatraemia by free-water and effective osmole flux (Tables 2 and 3). Additionally, medications are an often-overlooked sodium burden (Table 4) [137].

Our approach to diagnosis of dysnatraemia (Figs. 9 and 10) begins by measurement of the excreted effective osmoles in comparison to the serum effective osmoles. This is simplified (initially) to the comparison of urinary sodium and potassium to $[\text{Na}^+]_p$, correcting the latter for $[\text{Glucose}]_p$ if hyperglycaemia is present (Figs. 11 and 12). We measure urinary losses first as they represent the body’s attempt to rectify the dysnatraemia. Dichotomisation based on urinary effective osmole concentrations classifies pathologies into those due to renal loss or other

Table 1 Summary of clinically relevant methods to measure sodium in a solution

Device	Method	Advantages	Disadvantages
Flame photometry	Alkali metal salts are ionized by a flame and emit light as electrons return to the ground state. The wavelength determines the metal species while the intensity determines the concentration	Does not need to be calibrated regularly	Subject to spurious results “pseudohyponatraemia” in the setting of hyperlipidaemia, hyperproteinaemia or any other state of altered plasma water to plasma ratio “Pseudohypernatraemia” may also occur in altered plasma water to plasma ratio (usually hypoproteinaemia)
Ion-specific electrode	An electrode permeable to a specific species allows a potential gradient to form across it, which is proportional to the activity of that ion as per the Nernst equation. Activity must then be converted to concentration*		
	Indirect ion-specific electrode	A sample of whole plasma is diluted with a relatively large volume of buffer of high ionic strength, so that the activity coefficient is constant	Result similar to flame photometry
	Direct ion-specific electrode	The activity of a sample of whole plasma is converted to a concentration assuming constant activity coefficients for the standards, calibrators and samples	Not effected by states of altered plasma water to plasma ratio as measures electrolyte content in the plasma water (mmol/kg H ₂ O)
			The electrochemical activity of the ions in the water is converted to the readout concentration by a fixed (ion-specific) multiplier. This is only accurate for a given ionic strength, usually chosen to equal 160 mmol/L for plasma, and thus is less accurate at extremes of sodium concentration

*= Activity is the product of concentration and the activity coefficient (which is defined by the Debye-Huckel equations). *ISE* ion-sensitive electrode

means. Note that the interpretation of plasma and urinary tonicities required for diagnosis and treatment differ slightly.

When urinary tonicity is less than plasma tonicity (i.e. $([Na^+]_u + [K^+]_u) < [Na^+]_p$), the kidney is expelling net free-water from the body. In the setting of hyponatraemia, if AVP is fully suppressed (the appropriate response to low plasma tonicity), urinary tonicity should be much less than plasma tonicity (i.e. $([Na^+]_u + [K^+]_u) \ll [Na^+]_p$). If urinary tonicity is not suppressed, even if it lower but similar to plasma, this response is considered abnormal, as the physiological response to hyponatraemia is maximally dilute urine. In the setting of hypernatraemia, a low urinary tonicity is inappropriate for plasma tonicity. When urinary tonicity is high $([Na^+]_u + [K^+]_u) > [Na^+]_p$, the kidney is retaining net free-water from the body. In the setting of hyponatraemia, this is inappropriate, while in hypernatraemia, it is appropriate for plasma tonicity. The same caveat applies such that a urinary tonicity just above that of plasma in hypernatraemia is still inappropriate, as urine should be maximally concentrated. A further caveat is if a previously renally driven process resolves prior to testing, only the restorative phase may be

captured biochemically, thus obscuring the diagnosis (but not effecting treatment).

Although we present a dichotomous approach, clinical application is often more blurred, and clinical reasoning is key. The thresholds presented should not be seen as absolutes, but as guides (see Appendix 1).

Free-water clearance as a guide to management

Calculation of the (electrolyte) free-water clearance (E_{FWC}) of the kidney can be helpful to conceptualize the physiology underlying the treatment of dysnatraemias (Fig. 13). Urine volume (V_{urine}) is described as being comprised of two components, one that is isotonic to plasma, and another that is (electrolyte) free-water. When E_{FWC} is positive, this is volume of free-water being excreted per unit time (e.g. per day) by the kidney; when negative, it is the volume of free-water being retained [101]:




Fig. 8 Comparison of the methods of calculating sodium concentration in plasma with different compositions. Plasma is generally composed of 93% water, with proteins and lipids (together the “solid phase”) accounting for the remaining 7%. The D-ISE measures the thermodynamic activity of sodium in plasma water, which generally follows its concentration, although other species in the plasma, namely, chloride, may alter this. The thermodynamic activity of sodium is then divided by an activity coefficient to yield the concentration of sodium in plasma water. Finally, this value is corrected to match the values produced by I-ISE and FP methods, assuming the plasma contains 7% solid phase. I-ISE and FP require dilution prior to sampling, which introduces dilutional error. Moreover, the I-ISE and FP methods, by

virtue of this dilution step, measure the sodium concentration in whole plasma, as opposed to the sodium concentration in plasma water measured by D-ISE. Importantly, the former may produce spurious results in the setting of elevated or decreased plasma solid phase. Spuriously low values are seen in states where the lipid or protein component of plasma is increased, the so-called pseudohyponatraemia, and spuriously high values in the setting of hypoproteinaemia. D-ISE measurements are not affected by changes in plasma solid phase. Modified from Fortgens P, Pillay TS. Pseudohyponatraemia revisited: a modern-day pitfall. Arch Pathol Lab Med. 2011;135:516. ©2010 College of American Pathologists

Table 2 Causes of hyponatraemia classified by free-water and effective osmole flux

Hyponatraemia	
Increased free-water intake	Decreased effective osmole intake
Polydipsia	Malnutrition
Hypotonic fluids*	
Surgical irrigation	
Decreased free-water output	Increased effective osmole output
SIAD	Renal losses
Physiologically appropriate increase in AVP (states of decreased effective intravascular volume, e.g. HF, CLD, sepsis, hypothyroidism)	Diuretics (primarily thiazides)
	CRSW
	Hypocortisolaemia
	Hypoaldosteronaemia
	Hypothyroidism
	Salt losing nephropathy
	Non-renal losses
	Bleeding
	GIT losses with high effective osmolarity (e.g. secretory diarrhoea)
	Burns

*= Note any fluid with an effective osmolar concentration less than the average of the effective osmolar concentrations of all excretions will lower the serum sodium. Remember to consider the osmotic coefficient of the solute in the fluid
HF heart failure, *CLD* chronic liver disease, *AVP* arginine vasopressin (antidiuretic hormone), *SIAD* syndrome of inappropriate antidiuresis, *CRSW* cerebral-renal salt wasting, *GIT* gastrointestinal tract

Table 3 Causes of hyponatraemia classified by free-water and effective osmole flux

Hyponatraemia	
Decreased free-water intake	Increased effective osmole intake
No access to water	Medications (see Table 4)
NPO	Hypertonic fluids*
Loss of thirst drive (e.g. hypothalamic lesions)	Salt poisoning
Increased free-water output	Decreased effective osmole output
Renal losses	Rarely a cause of clinically important hyponatraemia
DI (central and nephrogenic)	Hyperaldosteronaemia
Osmotic diuresis (e.g. hyperglycaemia, mannitol, urea)	Hypercortisolaemia
Reduced renal concentrating capacity (e.g. myeloma, ATN, TIN)	Glucocorticoids
Non-renal losses	
Sweating	
Osmotic diarrhoea	
Respiratory losses (e.g. high flow oxygen without humidifier)	

*= Note any fluid with an effective osmolar concentration greater than the average of the effective osmolar concentrations of all excretions will increase the serum sodium. Remember to consider the osmotic coefficient of the solute in the fluid

NPO nil per Os, *DI* diabetes insipidus, *ATN* acute tubular necrosis, *TIN* tubulointerstitial nephritis

$$EFWC \approx V_{urine} \cdot \left(1 - \frac{([Na^+]_u + [K^+]_u)}{[Na^+]_p} \right)$$

Table 4 Common medications with a high sodium load

Drug (route)	Sodium per dose (mmol)
Piperacillin/tazobactam 4 g/500 mg (IV)	9.4
Ampicillin 2 g (IV)	5.7
Ceftriaxone 2 g (IV)	7.2
Meropenem 1 g (IV)	3.9
Ceftazidime 2 g (IV)	4.7
Omeprazole 40 mg (PO)	13.2
Macrogol 3350 (Movicol®) (1 sachet)	65
1000 ml of 0.9% NaCl	154
100 ml of 3% NaCl	51
20 ml of 23.4% NaCl	80
1000 ml of compound sodium lactate	130

PO per oral, *IV* intravenous

Sodium per dose is given as the intrinsic sodium for the dose of antibiotic only. Additional sodium may be present when administered in a “ready to use” pack or when reconstituted in saline. Note that many intravenous medications are administered in 100–250 ml solutions of 0.9% saline, which increases their sodium load. For example, QID dosing of piperacillin/tazobactam 4 g/500 mg reconstituted in 100 ml 0.9% sodium chloride equates to ~ 100 mmol of sodium

Insensible losses (trans-epidermal and respiratory) must also be considered in the clearance pathways of free-water. Sweat and gastrointestinal losses also contribute; however, they contain variable amounts of solute.

Electrolyte free-water intake (EFWI) is conceptually similar to EFWC, being the amount of free-water entering the body:

$$EFWI \approx V_{intake} \cdot \left(1 - \frac{([Na^+]_{intake} + [K^+]_{intake})}{[Na^+]_p} \right)$$

Production of metabolic water is an additional source of free-water.

Electrolyte free-water balance (EFWB) has therefore been defined as the difference between EFWI and EFWC [9, 10]:

$$EFWB = EFWI + \text{Metabolic Water} - EFWC - \text{Insensible Losses}$$

The clinical consequences of these equations are that in the setting of hyponatraemia:

When EFWC is positive, the kidneys are expelling free-water. If EFWI can be made less than EFWC (e.g. by restriction of free-water intake), hyponatraemia should resolve (see Supplemental content 1).

When EFWC is negative, the kidneys are retaining free-water. Here, EFWC may be increased by AVP




Fig. 9 An approach to the diagnosis of hyponatraemia. ACR, albumin/creatinine ratio (urine); BNP, brain natriuretic peptide; BSL, blood sugar level; CRSW, cerebral renal salt wasting; D-ISE, direct ion-sensitive electrode; DKA, diabetic ketoacidosis; ECF, extracellular fluid; FE_{Na}, fractional excretion of sodium; FE_{Urate}, fractional excretion of urate; GIT, gastrointestinal tract; HHS, hyperglycaemic hyperosmolar; I-ISE,

indirect ion-sensitive electrode; INR, international normalized ratio; IV-Ig, intravenous immunoglobulin; LFTs, liver function tests; PCR, protein/creatinine ratio (urine); SIAD, syndrome of inappropriate antidiuresis; SPEP, serum protein electrophoresis; TTE, transthoracic echocardiogram; UEC, urea, electrolytes and creatinine; UPEP, urine protein electrophoresis; USS, ultrasound

antagonism or EFWI may be made negative by restriction of free-water intake and prescription of hypertonic substances (e.g. salt tablets, 3% saline).

Differentiating the cause of increased AVP in hyponatraemia

Both hypovolaemia and SIAD demonstrate elevated AVP. Differentiation is complex, reliant on the amalgam of clinical history, physical signs and response to treatment. Physiologically, the difference lies in the state of the RAA axis, normal in SIAD and upregulated in hypovolaemia (Fig. 14). Differentiation is critical as volume replacement will improve hyponatraemia in hypovolaemia, but worsen it in SIAD. Conversely, free-water restriction below EFWC will lead to improvement in SIAD but not in hypervolaemia, as the primary stimulus has not been addressed.

Several markers have been proposed to assess the RAA axis in hyponatraemia, but none has proved effective in

isolation. A low [Na⁺]_u (< 20 mmol/L) is common in hypovolaemia and, if present, permits volume replacement without risk of worsening hyponatraemia. However, [Na⁺]_u may be elevated (> 40 mmol/L) in hypovolaemia and renal salt wasting: *not all elevated [Na⁺]_u is SIAD*.

Tubular handling of different solutes can be estimated using their fractional excretion, the percentage of the filtered solute that is lost in the urine:

$$FE_{\text{Solute}}(\%) = 100 \cdot \frac{[\text{Solute}]_{\text{urine}} \cdot [\text{Cr}]_{\text{plasma}}}{[\text{Solute}]_{\text{plasma}} \cdot [\text{Cr}]_{\text{urine}}}$$

A low fractional excretion of sodium (FE_{Na}) (< 0.5%) is one sign the RAA is upregulated and the kidney is retaining most of its filtered sodium. In small studies, a FE_{Na} < 0.5% predicted improvement of hyponatraemia with saline administration [96, 97]. When glomerular filtration rate is high and sodium intake is low, FE_{Na} may also be suppressed, even in the absence of hypovolaemia. The addition of a low (< 55%) fractional excretion of urea (FE_{Urea}) or a low (< 12–17%) fractional excretion of uric acid (urate) (FE_{UA}) to an FE_{Na} < 0.5% improves specificity for saline responsiveness [38, 96, 97].




Fig. 10 An approach to the diagnosis of hyponatraemia. DI, diabetes insipidus; D-ISE, direct ion-sensitive electrode; ECF, extracellular fluid; FE_{Na}, fractional excretion of sodium; FE_{Urate}, fractional excretion of

urate; I-ISE, indirect ion-sensitive electrode; MR, magnetic resonance imaging; SPEP, serum protein electrophoresis

Tracking of FE_{Na} and [Na⁺]_u after a volume loading can also be useful, as SIAD is associated with an increase in FE_{Na} but persistently elevated [Na⁺]_u.

Differentiation between SIAD and CRSW using FE_{Na} or FE_{UA} unfortunately can only be performed retrospectively after correction of serum sodium (FE_{urate} corrects in SIAD, while is persistently elevated in CRSW), limiting its clinical utility [87, 88]. Non-specific markers of the volume depletion of CRSW (cf. SIAD) include an elevated urea/creatinine ratio and haematocrit.

Symptoms of dysnatraemia

Cerebral symptoms in dysnatraemias [43] (Fig. 15) are related to the degree of dysnatraemia and the tempo at which it developed, with more acute and severe changes associated with worse symptoms [13].

Management of hyponatraemia


Treatment of hyponatraemia (Fig. 16) depends on clinical context. Those with cerebral symptoms should be treated urgently with hypertonic solutions. After SAH, volume

restriction increases the risk of DCI and alternative treatments are required [140]. In individuals with hypovolaemic hyponatraemia with renal salt wasting (CRSW or other), free-water restriction must be employed in concert with volume replacement to avoid worsening hypovolaemia. In most other clinical contexts, free-water restriction should be considered first-line therapy. Additional therapies include increasing effective osmole intake and possibly increasing EFWC using loop diuretics or antagonists of the AVP axis. These should be used judiciously and only employed when EFWC is low (< 500 ml/day) or negative. Given that the equations predicting the response of [Na⁺]_p to treatment are not accurate [48, 78], we suggest monitoring of serum and urinary electrolytes every 1–2 h during active treatment and twice daily when treating with free-water restriction alone.

Symptomatic hyponatraemia

Symptomatic hyponatraemia should always be treated by intravenous hypertonic fluid (e.g. 3% saline). The goal is to rapidly increase [Na⁺]_p by 4–6 mmol/L to prevent progression of cerebral oedema and herniation [128]. The guidelines recommend infusion of 150 ml of 3% saline over 20 min, followed by a repeat infusion once a repeat plasma sample has been

Fig. 11 Derivation of plasma and urine tonicity. The osmolarity of both plasma and urine differs from their tonicity by the inclusion of urea, which is an ineffective osmole. Plasma tonicity can be simplified to twice the sodium concentration given that potassium and glucose levels are highly regulated within a narrow range. Urine tonicity can be approximated to twice the sodium potassium sum, as substantial glycosuria occurs only in the setting of profound hyperglycaemia or a Fanconi syndrome. We can halve these approximations to more easily compare urinary tonicity ($[\text{Na}^+]_u$ and $[\text{K}^+]_u$) to plasma tonicity $[\text{Na}^+]_p$. DKA, diabetic ketoacidosis; ECF, extracellular fluid; HHS, hyperglycaemic hyperosmolar syndrome



taken [125]. This process should be repeated until a 5 mmol/L rise in $[\text{Na}^+]_p$ has been achieved. Infusion of 3% saline should then be continued until symptoms resolve or a 10 mmol/L rise in plasma sodium has been achieved, aiming for a rise of 1 mmol/L/h.

Hyponatraemia in the setting of intracranial catastrophe

Volume restriction in the presence of intracranial catastrophe is associated with poor outcome [140], and the treatment for hyponatraemia in these settings is salt. The volume state should be maintained with isotonic (0.9%) saline, and all efforts should be made to limit the administration of hypotonic fluids (such as reconstituting medications in saline as opposed to dextrose solutions). Free-water should be restricted as much as possible. If EFWC is substantially negative, or $[\text{Na}^+]_p$ continues to decline, second-line agents include salt tablets, continuous, slow infusion of 3% saline (e.g. 20 ml/h) and mineralocorticoids (fludrocortisone) [107]. The latter has not been shown to improve outcome after SAH [94, 120] and may increase the risk of hypokalaemia.

Free-water restriction

Restriction of free-water intake reduces EFWI and thus EFWB, therefore ameliorating hyponatraemia. Restriction of free-water intake is often all that is required to treat hyponatraemia when the volume restriction can reasonably

be made lower than EFWC. The restriction of free-water intake must be lower than EFWC to be effective in isolation; thus, in those with low (e.g. <500 ml per day) or negative EFWC, an additional strategy is commonly employed.

Intravenous volume replacement

When volume depletion is driving AVP secretion, intravenous crystalloid volume replacement facilitates physiological suppression of AVP secretion. Those with a reduced $\text{FE}_{\text{Na}/\text{UA}/\text{Urea}}$ have an upregulated RAA axis and will likely respond to volume replacement. Those with a normal or elevated $\text{FE}_{\text{Na}/\text{UA}/\text{Urea}}$ may be renally salt wasting (respond to volume replacement) or have SIAD (worsen with fluid administration). Because differentiation is impossible biochemically, volume replacement should only be trialled after free-water restriction alone is unsuccessful and clinical suspicion of SIAD is low, as hyponatraemia from SIAD may worsen with crystalloid.

Increasing effective osmole intake

Effective osmoles (salt tablets or hypertonic saline infusion) can be conceptualized as decreasing EFWI (and EFWB). These are particularly useful in individuals with negative EFWC, where free-water restriction alone is insufficient. In the asymptomatic, salt tablets or high-dose urea [31] provide a noninvasive method of increasing effective osmole intake, so long as the dose is great enough to saturate urea transport




Fig. 12 Using the urinary sodium potassium sum to classify dysnatraemias. When the urinary sodium ($[Na^+]_u$) potassium ($[K^+]_u$) sum is greater than the serum sodium (i.e. $([Na^+]_u + [K^+]_u) > [Na^+]_p$) (purple boxes), renal output is causing free-water to be retained and AVP levels are high. In the setting of hyponatraemia, whether this elevated AVP is an appropriate physiological response to a decreased effective volume state or is non-physiological (i.e. SIAD) requires further investigation. Furthermore, a urinary sodium potassium sum that is slightly less than the serum sodium in a hyponatraemic individual is still grossly abnormal, as ADH should suppress completely, and points towards renal free-water retention (see Appendix 1). In the setting of hypernatraemia, this is the appropriate physiological response and the


cause of the hypernatraemia is likely non-renal. The caveat is a previously renally driven process that resolves prior to testing, where only the restorative phase is captured biochemically. Conversely, when the urinary sodium potassium sum is less than the serum sodium (i.e. $([Na^+]_u + [K^+]_u) < [Na^+]_{pw}$) (green boxes), renal output is causing excretion of free-water, and AVP levels are low (or the kidney is not responding appropriately to circulating AVP, i.e. nephrogenic DI). In the setting of hyponatraemia, this suppressed AVP is an appropriate physiological response and the cause is likely non-renal (with the same caveat as above). In the setting of hypernatraemia, this lack of AVP effect is pathological and points to a lesion along the AVP axis, from hypothalamus to kidney

mechanisms in the collecting duct [40]. Salt tablets and urea have both successfully been used in chronic SIAD resistant to fluid restriction [81]. Of interest, high-dose urea (15 g) has been shown to simultaneously reduce intracranial pressure (ICP) and raise $[Na^+]_p$ in hyponatraemic patients with intracranial catastrophe [11]. Crucially, salt tablets or other effective osmoles are not appropriate in hypervolaemic hyponatraemia. Here, there is adequate (if not surplus) total body effective osmoles; they are just not in the intravascular space. Management here relies on improvement of haemodynamics through vasomediators, albumin and diuretics.

Increasing urinary free-water clearance

Loop diuretics, by virtue of interfering with the countercurrent concentrating mechanism of the nephron, ameliorate the fixed urinary diluting capacity seen with increased AVP. Thus, when combined with increased solute intake, they can augment treatment in SIAD. Importantly, they also increase kaliuresis, and serum potassium should be monitored throughout therapy.

EFWC can be increased by V2-antagonists (“-vaptans”), useful in those with a negative EFWC but dangerous in those with hypovolaemic hyponatraemia. The role of vaptans in






Fig. 15 Symptoms of hyponatraemia and hypernatraemia. Note that acute changes in tonicity generally present with earlier, more severe symptoms. Cerebral symptoms of dysnatraemias generally occur in those in whom a precipitous drop in $[Na^+]_p$ occurred within 48 h, as it is thought that this is the length of time neurons and glia require to alter their intracellular tonicity to match that of the ECF. In a study of 65 individuals with $[Na^+]_p < 128$ mmol/L, all those in whom the hyponatraemia developed within 48 h were symptomatic. For those in whom the hypernatraemia was

chronic (present for >48 h), symptomatic individuals had a mean $[Na^+]_p$ of 115 mmol/L (cf. 122 mmol/L in the asymptomatic). All individuals in whom seizures developed had a $[Na^+]_p < 121$ mmol/L. Precipitous rises in plasma sodium concentration are associated with a rapid decrease in brain volume leading to rupture of cerebral vessels and consequently intracerebral, subdural and subarachnoid haemorrhages, as well as osmotic demyelination

may promote bleeding [1], and conivaptan, which also inhibits the V1a receptor, may particularly promote bleeding given the role of the V1a receptor in platelet aggregation [58]. Given their variable efficacy and potential for uncontrolled aquaresis, “vaptans” are not recommended for routine use in hyponatraemia.

Management of hypernatraemia

Our approach to the treatment of hypernatraemia (Fig. 17) depends on clinical context. Those with cerebral symptoms due to hypernatraemia must be treated urgently with free-water and consideration of DDAVP. In asymptomatic individuals, slow correction (<6 mmol/L/day) is associated with greater morbidity [8] while overzealous correction (>24 mmol/L/day) may be associated with cerebral oedema [37]. The volume state is more often deranged than in hyponatraemia and thus should be corrected simultaneously.

Acute, symptomatic hypernatraemia

Acute hypernatraemia due to DI or salt intoxication may be symptomatic. Free-water in the form of intravenous 5% dextrose should be given, and an initial rate of 4–6 ml/kg/h is reasonable. Because of the time required for cerebral

adaptation, $[Na^+]_p$ may be rapidly normalized with impunity. DDAVP may be required as an adjunct in those with central DI.

Free-water

The thirst mechanism will generally maintain plasma tonicity within a narrow range, and thus hypernatraemia is seen primarily in individuals who cannot experience or respond to thirst normally; this may be exacerbated by diuretics, vomiting or diarrhoea [102]. In asymptomatic individuals with adequate mentation, free oral water is appropriate. Five percent of dextrose is equivalent to free-water and may be given intravenously at a rate of 1–1.5 ml/kg/h. Hyperglycaemia is a potential complication of large dextrose loads and may cause a transient fluid shift that obfuscates the true severity of the hypernatraemia. Plasma glucose should be measured at the same intervals as electrolytes, and 5% dextrose may be replaced with pure water infused directly into the right atrium in refractory hyperglycaemia.

AVP analogues

AVP analogues should be utilized in central DI when it is difficult to match urinary losses with oral intake, such as with impaired mentation or large urinary losses, especially




Fig. 16 An approach to the management of hyponatraemia. Note the early and important distinction between those with acute and symptomatic hyponatraemia and those with chronic and asymptomatic hyponatraemia. Those with cerebral symptoms should be treated urgently with hypertonic solutions. After SAH or other intracranial catastrophes, free-water restriction increases the risk of DCI and alternative treatments are required. In individuals with hypovolaemic hyponatraemia with renal salt wasting (CRSW or other), free-water restriction must be employed in concert with volume replacement to avoid worsening hypovolaemia. In most other clinical contexts, free-water restriction should be considered

overnight. Desmopressin is the most common agent, available as a tablet, nasal spray and injectable. Duration of effect depends on dose and route of administration with moderate inter-individual variability.

Effective osmole restriction and effective osmole excretion

Less commonly, hypernatraemia may occur due to excessive effective osmole intake. This hypernatraemia can only be sustained if accompanied by either impaired access to free-water or renal dysfunction because of hypovolaemia or concentrating defect. Here, treatment consists of reduction of unnecessary effective osmole intake, provision of free-water and

first-line therapy. Additional therapies include increasing effective osmole intake and possibly increasing EFWC using loop diuretics or antagonists of the AVP axis. These should be used judiciously and only employed when EFWC is low (<500 ml/day) or negative. CCF, congestive cardiac failure; CRSW, cerebral renal salt wasting; DDAVP, desmopressin; EFWC, effective free-water clearance; FE_{Na} , fractional excretion of sodium; IV, intravenous; ODS, osmotic demyelination syndrome; PO, per oral; PRN, as needed; SAH, subarachnoid haemorrhage; SIAD, syndrome of inappropriate antidiuresis; TDS, three times a day; QID, four times a day

creation of negative cation balance using thiazides or, if necessary, renal replacement therapy.

Complications of dysnatraemia management

Osmotic demyelination syndrome

If the magnitude and rapidity of correction of chronic hyponatraemia (present for >48 h) is too great, pontine and extrapontine myelinolysis occur, presenting as rapidly progressive paraparesis or tetraparesis with pseudobulbar findings, usually delayed 2–6 days after correction (Fig. 18). An increased risk of ODS is seen in those with substantial hyponatraemia ($[Na^+]_p < 105$ mmol/L), hypokalaemia,




Fig. 17 An approach to the management of hypernatraemia. DI, diabetes insipidus; IV, intravenous; PO, per oral

alcoholism, malnutrition and cirrhosis [136]. Generally, ODS does not occur unless [Na⁺]_p rises by > 10 mmol/L in 24 h or > 18 mmol/L in 48 h [83]; however, in asymptomatic individuals, there is no benefit in raising the serum sodium at > 6 mmol/L/24 h [12]. Thus, for asymptomatic individuals, we avoid a rise in [Na⁺]_p by > 10 mmol/L/24 h, while in high risk groups (vide supra) a more conservative goal (e.g. < 6–8 mmol/L/24 h) is appropriate. Overcorrection of [Na⁺]_p can be promptly reversed with 5% dextrose or DDAVP. These individuals should be managed in an intensive care unit with endocrinologist and intensivist input.

Cerebral oedema

Cerebral oedema occurs if the magnitude and rapidity of correction of chronic, generally severe (> 155 mmol/L) hypernatraemia, are too great and relative reduction in tonicity results in cellular swelling. Unlike hyponatraemia, there is no clear evidence in adults for limiting the rate of correction [127]. Indeed, correction at a rate of > 0.5 mmol/L/h (> 12 mmol/L/day) produced similar outcomes to more conservative sodium lowering [22]. If signs of increased ICP do occur, a hypertonic saline bolus can be administered.

Conclusion

A summary of the take-home points regarding the diagnosis and management of disorders of water balance in neurocritically ill patients is given below.

Normal physiology

- The renal renin-angiotensin-aldosterone axis (RAA) is the primary mechanism of volume (combined solute and solvent) homeostasis. Increased RAA activity leads to volume retention with no substantial change in free-water balance as both solute and solvent are retained concurrently.
- The central AVP axis is the primary mechanism of free-water homeostasis. AVP secretion causes free-water retention and thus an altered balance of solute to solvent, leading to decreased plasma sodium (solute) concentration.
- AVP maintains tonicity unless substantial (> 10%) hypovolaemia occurs. Then, defence of tonicity is sacrificed for the defence of volume, and the body must tolerate hypotonicity to maintain euvolaemia.
- Sodium, potassium and free-water flux are the primary determinants of the serum sodium concentration.




Fig. 18 Typical appearance of pontine osmotic demyelination. This patient presented with a $[\text{Na}^+]_p$ of 107 mmol/L in the setting of malnutrition and primary polydipsia. Over the course of 24 h, $[\text{Na}^+]_p$ rose 18 mmol/L, and in 48 h it had normalized. Three days after presentation, the patient became comatose, and MR imaging (T2-FLAIR sequence shown) demonstrated pontine myelinolysis

- Urea is not an effective osmole and thus urinary osmolality does not correlate well with urinary tonicity. The latter is the clinically important variable

Pathological states

- Hyponatraemia is a disorder of too much free-water; hypernatraemia is a disorder of too little free-water. Thus, plasma sodium concentration is an effective marker of total body free-water.
- Hypernatraemia will only occur in the setting of an impaired thirst mechanism or inadequate access to free-water.

Analysis

- The sodium concentration in the blood is slightly greater than that of the interstitial fluid due to the pull of plasma proteins (Gibbs-Donnan effect). This is negated by compensatory underestimation of plasma water sodium by measurement devices.
- In states of hyperlipidaemia, hyperproteinaemia or hypoproteinaemia, sodium values reported on formal pathology may be spuriously low or high, respectively, due to alteration of the ratio of plasma water to solid phase.
- Pseudohyponatraemia and pseudohypernatraemia should *not* be considered when analysing results from point-of-care analysers (“blood-gas machines”).

- Effective osmoles in large concentrations, such as glucose, mannitol and glycols, may produce translocational hyponatraemia or hyperosmolar hyponatraemia.
- Always correct the serum sodium for the glucose concentration in the setting of hyperglycaemia.

Clinical points

- In the absence of overt volume overload (peripheral pitting and/or alveolar oedema) or overt hypovolaemia (hypotension, postural hypotension and tachycardia), the volume state is very difficult to discern clinically.
- Medications and fluid losses other than urine are often overlooked causes of hyponatraemia.
- All hyponatraemias should be presumed to be chronic unless there is biochemical evidence of its acuity (i.e. a normal serum sodium within the last 48 h).

Assessment

- Dysnatraemias can be classified by the flux of water and solute and by the renal response to dysnatraemia.

When $([\text{Na}^+]_u + [\text{K}^+]_u)$ exceeds $[\text{Na}^+]_p$, renal output is causing free-water to be retained.

When $([\text{Na}^+]_u + [\text{K}^+]_u)$ is less than $[\text{Na}^+]_p$, renal output is causing excretion of free-water.

When $([\text{Na}^+]_u + [\text{K}^+]_u)$ is much less than $[\text{Na}^+]_p$, absolute (or functional) AVP levels are low.

When $([\text{Na}^+]_u + [\text{K}^+]_u)$ approaches or exceeds $[\text{Na}^+]_p$, AVP is being secreted

- When EFWC is negative, the kidney is retaining free-water, lowering the serum sodium concentration. Conversely, when EFWC is positive, the kidney is excreting free-water.
- If free-water intake is greater than EFWC and the balance of insensible losses and metabolic water, serum sodium will fall. Thus, free-water restriction should be based on EFWC and, when substantial, GI losses.
- AVP activation is seen in severe hypovolaemia (renal and non-renal salt wasting) and SIAD and is associated with an elevated $[\text{Na}^+]_u$.

Management

- As a rule of thumb, the volume state can be controlled with normal saline, while water balance can be controlled with free-water restriction or salt (salt tablets, hypertonic saline).
- Individuals with intracranial catastrophe and moderate/severe hyponatraemia should be treated with salt and volume replacement, as volume restriction is associated with poor outcome.

- Patients with cerebral symptoms (decreased conscious state or seizures) due to hyponatraemia should be treated with hypertonic saline.
- Those with asymptomatic hyponatraemia should be initially treated with free-water restriction.
- Options when free-water restriction alone fails to improve hyponatraemia include adding salt (salt tablets, hypertonic saline), loop diuresis or AVP antagonism (in descending order of safety).
- Those in which hypovolaemia is thought to be driving AVP secretion in hyponatraemia should receive volume replacement. This can be safely administered when $[Na^+]_u$ is low (e.g. <20). When $[Na^+]_u$ is elevated (e.g. >40), hypovolaemia may still be driving the hyponatraemia, but SIAD needs to be considered. If volume replacement is trialled, $[Na^+]_p$ should be monitored closely.
- Those with obvious hypervolaemia and hyponatraemia should be free-water restricted and the volume state corrected as possible.
- Overcorrection of sodium in patients with chronic hyponatraemia (present >48 h), defined as >10 mmol/L in 24 h or >18 mmol/L in 48 h, introduces the risk of osmotic demyelination syndrome. Patients with hypokalaemia, alcoholism, malnutrition and cirrhosis are at increased risk, and a target of 6–8 mmol/L/day is presumed to be safest.
- Hypernatraemia should be treated with free-water, preferably orally if tolerated. AVP analogues can be used when oral intake cannot match urinary losses.
- Evidence for limiting the rate of correction in hypernatraemia is lacking in adults. However, limits from studies in the paediatric population are commonly applied to adults (e.g. <12 mmol/L/day).

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s10143-020-01450-9>.

Declarations No part of this article has been previously published or presented and no funding was acquired for the study.

All authors approved the final submission and all authors agree to be accountable for all aspects of the work.

Data availability Not applicable.

Compliance with ethical standards

Conflict of interest The authors have no conflicts of interest to disclose.

Ethics approval Not applicable.

Consent to participate Not Applicable.

Consent for publication Not applicable.

References

1. Aditya S, Rattan A (2012) Vaptans: a new option in the management of hyponatremia. *Int J Appl Basic Med Res* 2:77–78. <https://doi.org/10.4103/2229-516X.106347>
2. Agha A, Rogers B, Mylotte D, Taleb F, Tormey W, Phillips J, Thompson CJ (2004) Neuroendocrine dysfunction in the acute phase of traumatic brain injury. *Clin Endocrinol* 60:584–591
3. Agha A, Thornton E, O'Kelly P, Tormey W, Phillips J, Thompson CJ (2004) Posterior pituitary dysfunction after traumatic brain injury. *J Clin Endocrinol Metab* 89:5987–5992. <https://doi.org/10.1210/jc.2004-1058>
4. Agha A, Sherlock M, Phillips J, Tormey W, Thompson CJ (2005) The natural history of post-traumatic neurohypophysial dysfunction. *Eur J Endocrinol* 152:371–377. <https://doi.org/10.1530/eje.1.01861>
5. Aimaretti G, Ambrosio MR, Di Somma C, Fusco A, Cannavo S, Gasperi M, Scaroni C, De Marinis L, Benvenga S, degli Uberti EC, Lombardi G, Mantero F, Martino E, Giordano G, Ghigo E (2004) Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. *Clin Endocrinol* 61:320–326
6. Aiyagari V, Deibert E, Diringer MN (2006) Hypernatremia in the neurologic intensive care unit: how high is too high? *J Crit Care* 21:163–172. <https://doi.org/10.1016/j.jcrc.2005.10.002>
7. Ajlan AM, Abdulqader SB, Achrol AS, Aljamaan Y, Feroze AH, Katznelson L, Harsh GR (2018) Diabetes insipidus following endoscopic transsphenoidal surgery for pituitary adenoma. *J Neurol Surg B* 79:117–122
8. Alshayeb HM, Showkat A, Babar F, Mangold T, Wall BM (2011) Severe hypernatremia correction rate and mortality in hospitalized patients. *Am J Med Sci* 341:356–360. <https://doi.org/10.1097/MAJ.0b013e31820a3a90>
9. Anderson RJ, Chung HM, Kluge R, Schrier RW (1985) Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. *Ann Intern Med* 102:164–168
10. Andreoli DC, Whittier WL (2017) Reset osmostat: the result of chronic desmopressin abuse? *Am J Kidney Dis* 69:853–857. <https://doi.org/10.1053/j.ajkd.2016.12.009>
11. Annoni F, Fontana V, Brimioulle S, Creteur J, Vincent J-L, Taccone FS (2017) Early effects of enteral urea on intracranial pressure in patients with acute brain injury and hyponatremia. *J Neurosurg Anesthesiol* 29:400–405. <https://doi.org/10.1097/ANA.0000000000000340>
12. Arampatzis S, Frauchiger B, Fiedler GM, Leichtle AB, Buhl D, Schwarz C, Funk GC, Zimmermann H, Exadaktylos AK, Lindner G (2012) Characteristics, symptoms, and outcome of severe dysnatremias present on hospital admission. *Am J Med* 125:1125.e1–1125.e7. <https://doi.org/10.1016/j.amjmed.2012.04.041>
13. Arieff AI, Llach F, Massry SG (1976) Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. *Medicine (Baltimore)* 55:121–129
14. Berendes E, Walter M, Cullen P, Prien T, Van Aken H, Horsthemke J, Schulte M, Wild von K, Scherer R (1997) Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. *Lancet* 349:245–249. [https://doi.org/10.1016/S0140-6736\(96\)08093-2](https://doi.org/10.1016/S0140-6736(96)08093-2)
15. Berghuis B, van der Palen J, de Haan G-J, Lindhout D, Koeleman BPC, Sander JW (2017) Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. *Epilepsia* 58:1227–1233. <https://doi.org/10.1111/epi.13777>
16. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA (2005) Serum sodium predicts mortality in patients

- listed for liver transplantation. *Hepatology* 41:32–39. <https://doi.org/10.1002/hep.20517>
17. Bohl MA, Ahmad S, Jahnke H, Shepherd D, Knecht L, White WL, Little AS (2015) Delayed hyponatremia is the most common cause of 30-day unplanned readmission after transsphenoidal surgery for pituitary tumors. *Neurosurgery* 78:84–90
18. Boscoe A, Paramore C, Verbalis JG (2006) Cost of illness of hyponatremia in the United States. *Cost Eff Resour Alloc* 4:10. <https://doi.org/10.1186/1478-7547-4-10>
19. Castle-Kirschbaum M, Goldschlager T, Ho B, Wang YY, King J (2018) Twelve cases of pituitary metastasis: a case series and review of the literature. *Pituitary* 33:127–473. <https://doi.org/10.1007/s1102-018-0899-x>
20. Cesar KR, Magaldi AJ (1999) Thiazide induces water absorption in the inner medullary collecting duct of normal and Brattleboro rats. *Am J Phys* 277:F756–F760. <https://doi.org/10.1152/ajprenal.1999.277.5.F756>
21. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. *Hypertension* 49:839–845. <https://doi.org/10.1161/01.HYP.0000259805.18468.8c>
22. Chauhan K, Pattharanitima P, Patel N, Duffy A, Saha A, Chaudhary K, Debnath N, Van Vleck T, Chan L, Nadkarni GN, Coca SG (2019) Rate of correction of hypernatremia and health outcomes in critically ill patients. *Clin J Am Soc Nephrol* 14:656–663. <https://doi.org/10.2215/CJN.10640918>
23. Chin HX, Quek T, Leow M (2018) Central diabetes insipidus unmasked by corticosteroid therapy for cerebral metastases: beware the case with pituitary involvement and hypopituitarism. *J R Coll Physicians Edinb* 47:247–249. <https://doi.org/10.4997/JRCPE.2017.307>
24. Christ-Crain M, Bichet DG, Fenske WK, Goldman MB, Rittig S, Verbalis JG, Verkman AS (2019) Diabetes insipidus. *Nat Rev Dis Primers* 5:54–20. <https://doi.org/10.1038/s41572-019-0103-2>
25. Chung HM, Kluge R, Schrier RW, Anderson RJ (1987) Clinical assessment of extracellular fluid volume in hyponatremia. *Am J Med* 83:905–908
26. Cote M, Salzman KL, Sorour M, Couldwell WT (2014) Normal dimensions of the posterior pituitary bright spot on magnetic resonance imaging. *J Neurosurg* 120:357–362. <https://doi.org/10.3171/2013.11.JNS131320>
27. Cote DJ, Alzarea A, Acosta MA, Hulou MM, Huang KT, Almutairi H, Alharbi A, Zaidi HA, Algrani M, Alatawi A, Mekary RA, Smith TR (2016) Predictors and rates of delayed symptomatic hyponatremia after transsphenoidal surgery: a systematic review [corrected]. *World Neurosurg* 88:1–6. <https://doi.org/10.1016/j.wneu.2016.01.022>
28. Crowley RK, Sherlock M, Agha A, Smith D, Thompson CJ (2007) Clinical insights into adipsic diabetes insipidus: a large case series. *Clin Endocrinol* 66:475–482. <https://doi.org/10.1111/j.1365-2265.2007.02754.x>
29. Cusick JF, Hagen TC, Findling JW (1984) Inappropriate secretion of antidiuretic hormone after transsphenoidal surgery for pituitary tumors. *N Engl J Med* 311:36–38. <https://doi.org/10.1056/NEJM198407053110107>
30. D’Orazio P, Miller WG, Myers GL, Doumas BT (1995) Standardization of sodium and potassium ion-selective electrode systems to the flame photometric reference method: approved standard
31. Decaux G, Andres C, Kengne FG, Soupart A (2010) Treatment of euvoletic hyponatremia in the intensive care unit by urea. *Crit Care* 14:R184. <https://doi.org/10.1186/cc9292>
32. Dimeski G, Morgan TJ, Presneill JJ, Venkatesh B (2012) Disagreement between ion selective electrode direct and indirect sodium measurements: estimation of the problem in a tertiary referral hospital. *J Crit Care* 27:326.e9–326.16. <https://doi.org/10.1016/j.jcrc.2011.11.003>
33. Dorhout Mees SM, Hoff RG, Rinkel GJE, Algra A, van den Bergh WM (2011) Brain natriuretic peptide concentrations after aneurysmal subarachnoid hemorrhage: relationship with hypovolemia and hyponatremia. *Neurocrit Care* 14:176–181. <https://doi.org/10.1007/s12028-011-9504-0>
34. Eagles ME, Tso MK, Macdonald RL (2018) Significance of fluctuations in serum sodium levels following aneurysmal subarachnoid hemorrhage: an exploratory analysis. *J Neurosurg* 131:1–6. <https://doi.org/10.3171/2018.3.JNS173068>
35. Edelman IS, Leibman J, O’Meara MP, Birkenfeld LW (1958) Interrelations between serum sodium concentration, serum osmolality and total exchangeable sodium, total exchangeable potassium and total body water. *J Clin Invest* 37:1236–1256
36. Espiner EA, Leikis R, Ferch RD, MacFarlane MR, Bonkowski JA, Frampton CM, Richards AM (2002) The neuro-cardio-endocrine response to acute subarachnoid haemorrhage. *Clin Endocrinol* 56:629–635. <https://doi.org/10.1046/j.1365-2265.2002.01285.x>
37. Fang C, Mao J, Dai Y, Xia Y, Fu H, Chen Y, Wang Y, Liu A (2010) Fluid management of hypernatraemic dehydration to prevent cerebral oedema: a retrospective case control study of 97 children in China. *J Paediatr Child Health* 46:301–303. <https://doi.org/10.1111/j.1440-1754.2010.01712.x>
38. Fenske W, Störk S, Koschker A-C, Blechschmidt A, Lorenz D, Wortmann S, Allolio B (2008) Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics. *J Clin Endocrinol Metab* 93:2991–2997. <https://doi.org/10.1210/jc.2008-0330>
39. Fenske WK, Christ-Crain M, Hörning A, Simet J, Szinnai G, Fassnacht M, Rutishauser J, Bichet DG, Störk S, Allolio B (2014) A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis. *J Am Soc Nephrol* 25:2376–2383. <https://doi.org/10.1681/ASN.2013080895>
40. Fenton RA, Chou C-L, Sowersby H, Smith CP, Knepper MA (2006) Gamble’s ‘economy of water’ revisited: studies in urea transporter knockout mice. *Am J Physiol Ren Physiol* 291: F148–F154. <https://doi.org/10.1152/ajprenal.00348.2005>
41. Fernandez SJ, Barakat I, Ziogas J, Frugier T, Stylli SS, Laidlaw JD, Kaye AH, Adamides AA (2018) Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage. *J Neurosurg* 130:1–7. <https://doi.org/10.3171/2017.10.JNS17795>
42. Fortgens P, Pillay TS (2011) Pseudohyponatremia revisited: a modern-day pitfall. *Arch Pathol Lab Med* 135:516–519. <https://doi.org/10.1043/2010-0018-RS.1>
43. Fraser CL, Arieff AI (1997) Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. *Am J Med* 102: 67–77
44. Gamble JL, McKhann CF, Butler AM, Tuthill E (1934) An economy of water in renal function referable to urea. *Am J Phys* 109: 139–154. <https://doi.org/10.1152/ajplegacy.1934.109.1.139>
45. Ganong CA, Kappy MS (1993) Cerebral salt wasting in children. The need for recognition and treatment. *Am J Dis Child* 147:167–169. <https://doi.org/10.1001/archpedi.1993.02160260057022>
46. Gill G, Huda B, Boyd A, Skagen K, Wile D, Watson I, van Heyningen C (2006) Characteristics and mortality of severe hyponatraemia—a hospital-based study. *Clin Endocrinol* 65:246–249. <https://doi.org/10.1111/j.1365-2265.2006.02583.x>
47. Hamrahian AH, Oseni TS, Arafah BM (2004) Measurements of serum free cortisol in critically ill patients. *N Engl J Med* 350: 1629–1638. <https://doi.org/10.1056/NEJMoa020266>

48. Hanna RM, Yang W-T, Lopez EA, Riad JN, Wilson J (2016) The utility and accuracy of four equations in predicting sodium levels in dysnatremic patients. *Clin Kidney J* 9:530–539. <https://doi.org/10.1093/ckj/sfw034>
49. Hannon MJ, Finucane FM, Sherlock M, Agha A, Thompson CJ (2012) Clinical review: disorders of water homeostasis in neurosurgical patients. *J Clin Endocrinol Metab* 97:1423–1433. <https://doi.org/10.1210/jc.2011-3201>
50. Hannon MJ, Behan LA, O'Brien MMC, Tormey W, Ball SG, Javadpour M, Javadpur M, Sherlock M, Thompson CJ (2014) Hyponatremia following mild/moderate subarachnoid hemorrhage is due to SIAD and glucocorticoid deficiency and not cerebral salt wasting. *J Clin Endocrinol Metab* 99:291–298. <https://doi.org/10.1210/jc.2013-3032>
51. Harrigan MR (1996) Cerebral salt wasting syndrome: a review. *Neurosurgery* 38:152–160. <https://doi.org/10.1097/00006123-199601000-00035>
52. Hasan D, Wijdicks EF, Vermeulen M (1990) Hyponatremia is associated with cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. *Ann Neurol* 27:106–108. <https://doi.org/10.1002/ana.410270118>
53. Hayashi Y, Aida Y, Sasagawa Y, Oishi M, Kita D, Tachibana O, Ueda F, Nakada M (2018) Delayed occurrence of diabetes insipidus after transsphenoidal surgery with radiologic evaluation of the pituitary stalk on magnetic resonance imaging. *World Neurosurg* 110:e1072–e1077. <https://doi.org/10.1016/j.wneu.2017.11.169>
54. Heinbecker P, White HL (1939) The role of the pituitary gland in water balance. *Ann Surg* 110:1037–1049
55. Hensen J, Henig A, Fahlbusch R, Meyer M, Boehnert M, Buchfelder M (1999) Prevalence, predictors and patterns of post-operative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas. *Clin Endocrinol* 50:431–439
56. Hix JK, Silver S, Sterns RH (2011) Diuretic-associated hyponatremia. *Semin Nephrol* 31:553–566. <https://doi.org/10.1016/j.semnephrol.2011.09.010>
57. Hiyama TY, Utsunomiya AN, Matsumoto M, Fujikawa A, Lin C-H, Hara K, Kagawa R, Okada S, Kobayashi M, Ishikawa M, Anzo M, Cho H, Takayasu S, Nigawara T, Daimon M, Sato T, Terui K, Ito E, Noda M (2017) Adipsic hypernatremia without hypothalamic lesions accompanied by autoantibodies to subfornical organ. *Brain Pathol* 27:323–331. <https://doi.org/10.1111/bpa.12409>
58. Hline SS, Pham P-TT, Pham P-TT, Aung MH, Pham P-MT, Pham P-CT (2008) Conivaptan: a step forward in the treatment of hyponatremia? *Ther Clin Risk Manag* 4:315–326
59. Hughes F, Mythen M, Montgomery H (2018) The sensitivity of the human thirst response to changes in plasma osmolality: a systematic review. *Perioper Med (Lond)* 7:1–1632. <https://doi.org/10.1186/s13741-017-0081-4>
60. Intravooth T, Staack AM, Juerges K, Stockinger J, Steinhoff BJ (2018) Antiepileptic drugs-induced hyponatremia: review and analysis of 560 hospitalized patients. *Epilepsy Res* 143:7–10. <https://doi.org/10.1016/j.eplepsyres.2018.03.023>
61. Isotani E, Suzuki R, Tomita K, Hokari M, Monma S, Marumo F, Hirakawa K (1994) Alterations in plasma concentrations of natriuretic peptides and antidiuretic hormone after subarachnoid hemorrhage. *Stroke* 25:2198–2203. <https://doi.org/10.1161/01.str.25.11.2198>
62. Jovanovich AJ, Berl T (2012) Where vaptans do and do not fit in the treatment of hyponatremia. *Kidney Int* 83:563–567. <https://doi.org/10.1038/ki.2012.402>
63. Juul R, Edvinsson L, Ekman R, Frederiksen TA, Unsgård G, Gisvold SE (1990) Atrial natriuretic peptide-LI following subarachnoid haemorrhage in man. *Acta Neurochir* 106:18–23. <https://doi.org/10.1007/bf01809328>
64. Kao L, Al-Lawati Z, Vavao J, Steinberg GK, Katznelson L (2009) Prevalence and clinical demographics of cerebral salt wasting in patients with aneurysmal subarachnoid hemorrhage. *Pituitary* 12:347–351. <https://doi.org/10.1007/s11102-009-0188-9>
65. Khurana VG, Wijdicks EFM, Heublein DM, McClelland RL, Meyer FB, Piepgras DG, Burnett JC (2004) A pilot study of dendroaspis natriuretic peptide in aneurysmal subarachnoid hemorrhage. *Neurosurgery* 55:69–75– discussion 75–6. <https://doi.org/10.1227/01.neu.0000126877.10254.4c>
66. Klose M, Brennum J, Poulsen L, Kosteljanetz M, Wagner A, Feldt-Rasmussen U (2010) Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage. *Clin Endocrinol* 73:95–101. <https://doi.org/10.1111/j.1365-2265.2010.03791.x>
67. Lanterna LA, Spreafico V, Gritti P, Prodam F, Signorelli A, Biroli F, Aimaretti G (2013) Hypocortisolism in noncomatose patients during the acute phase of subarachnoid hemorrhage. *J Stroke Cerebrovasc Dis* 22:e189–e196. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.11.002>
68. le Roux CW, Chapman GA, Kong WM, Dhillon WS, Jones J, Alaghband-Zadeh J (2003) Free cortisol index is better than serum total cortisol in determining hypothalamic-pituitary-adrenal status in patients undergoing surgery. *J Clin Endocrinol Metab* 88:2045–2048. <https://doi.org/10.1210/jc.2002-021532>
69. Ledingham JG, Crowe MJ, Forsling ML, Phillips PA, Rolls BJ (1987) Effects of aging on vasopressin secretion, water excretion, and thirst in man. *Kidney Int Suppl* 21:S90–S92
70. Lee WH, Packer M (1986) Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. *Circulation* 73:257–267. <https://doi.org/10.1161/01.cir.73.2.257>
71. Lee P, Jones GRD, Center JR (2008) Successful treatment of adult cerebral salt wasting with fludrocortisone. *Arch Intern Med* 168:325–326. <https://doi.org/10.1001/archinternmed.2007.126>
72. Leier CV, Dei Cas L, Metra M (1994) Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. *Am Heart J* 128:564–574. [https://doi.org/10.1016/0002-8703\(94\)90633-5](https://doi.org/10.1016/0002-8703(94)90633-5)
73. Leonard J, Garrett RE, Salottolo K, Slone DS, Mains CW, Carrick MM, Bar-Or D (2015) Cerebral salt wasting after traumatic brain injury: a review of the literature. *Scand J Trauma Resusc Emerg Med* 23:98
74. Lester MC, Nelson PB (1981) Neurological aspects of vasopressin release and the syndrome of inappropriate secretion of antidiuretic hormone. *Neurosurgery* 8:735–740. <https://doi.org/10.1227/00006123-198106000-00020>
75. Levine JP, Stelnicki E, Weiner HL, Bradley JP, McCarthy JG (2001) Hyponatremia in the postoperative craniofacial pediatric patient population: a connection to cerebral salt wasting syndrome and management of the disorder. *Plast Reconstr Surg* 108:1501–1508. <https://doi.org/10.1097/00006534-200111000-00009>
76. Levy GB (1981) Determination of sodium with ion-selective electrodes. *Clin Chem* 27:1435–1438
77. Lindheimer MD, Barron WM, Davison JM (1989) Osmoregulation of thirst and vasopressin release in pregnancy. *Am J Phys* 257:F159–F169. <https://doi.org/10.1152/ajprenal.1989.257.2.F159>
78. Lindner G, Schwarz C, Kneidinger N, Kramer L, Oberbauer R, Druml W (2008) Can we really predict the change in serum sodium levels? An analysis of currently proposed formulae in hypernatraemic patients. *Nephrol Dial Transplant* 23:3501–3508. <https://doi.org/10.1093/ndt/gfn476>
79. Lipsett MB, Maclean JP, West CD, Li MC, Pearson OH (1956) An analysis of the polyuria induced by hypophysectomy in man. *J Clin Endocrinol Metab* 16:183–195. <https://doi.org/10.1210/jcem-16-2-183>

80. Little AS, Kelly DF, White WL, Gardner PA, Fernandez-Miranda JC, Chicoine MR, Barkhoudarian G, Chandler JP, Prevedello DM, Liebelt BD, Sfondouris J, Mayberg MR, TRANSSPHER Study Group (2019) Results of a prospective multicenter controlled study comparing surgical outcomes of microscopic versus fully endoscopic transsphenoidal surgery for nonfunctioning pituitary adenomas: the transsphenoidal extent of resection (TRANSSPHER) study. *J Neurosurg* 62:1–11. <https://doi.org/10.3171/2018.11.JNS181238>
81. Lockett J, Berkman KE, Dimeski G, Russell AW, Inder WJ (2019) Urea treatment in fluid restriction-refractory hyponatraemia. *Clin Endocrinol* 90:630–636. <https://doi.org/10.1111/cen.13930>
82. Lohani S, Devkota UP (2011) Hyponatremia in patients with traumatic brain injury: etiology, incidence, and severity correlation. *World Neurosurg* 76:355–360. <https://doi.org/10.1016/j.wneu.2011.03.042>
83. Lohr JW (1994) Osmotic demyelination syndrome following correction of hyponatremia: association with hypokalemia. *Am J Med* 96:408–413
84. Lord AS, Fernandez L, Schmidt JM, Mayer SA, Claassen J, Lee K, Connolly ES, Badjatia N (2012) Effect of rebleeding on the course and incidence of vasospasm after subarachnoid hemorrhage. *Neurology* 78:31–37. <https://doi.org/10.1212/WNL.0b013e31823ed0a4>
85. Lu X, Wang X (2017) Hyponatremia induced by antiepileptic drugs in patients with epilepsy. *Expert Opin Drug Saf* 16:77–87. <https://doi.org/10.1080/14740338.2017.1248399>
86. Lu DC, Binder DK, Chien B, Maisel A, Manley GT (2008) Cerebral salt wasting and elevated brain natriuretic peptide levels after traumatic brain injury: 2 case reports. *Surg Neurol* 69:226–229. <https://doi.org/10.1016/j.surneu.2007.02.051>
87. Maesaka JK, Fishbane S (1998) Regulation of renal urate excretion: a critical review. *Am J Kidney Dis* 32:917–933. [https://doi.org/10.1016/s0272-6386\(98\)70067-8](https://doi.org/10.1016/s0272-6386(98)70067-8)
88. Maesaka JK, Imbriano LJ, Ali NM, Ilamathi E (2009) Is it cerebral or renal salt wasting? *Kidney Int* 76:934–938. <https://doi.org/10.1038/ki.2009.263>
89. Maghnie M, Ghirardello S, De Bellis A, Di Iorgi N, Ambrosini L, Secco A, De Amici M, Tinelli C, Bellastella A, Lorini R (2006) Idiopathic central diabetes insipidus in children and young adults is commonly associated with vasopressin-cell antibodies and markers of autoimmunity. *Clin Endocrinol* 65:470–478. <https://doi.org/10.1111/j.1365-2265.2006.02616.x>
90. Maimaitili A, Maimaitili M, Rexidan A, Lu J, Ajimu K, Cheng X, Luo K, Sailike D, Liu Y, Kaheerman K, Tang C, Zhang T (2013) Pituitary hormone level changes and hyponatremia in aneurysmal subarachnoid hemorrhage. *Exp Ther Med* 5:1657–1662
91. Mapa B, Taylor BES, Appelboom G, Bruce EM, Claassen J, Connolly ESJ (2016) Impact of hyponatremia on morbidity, mortality, and complications after aneurysmal subarachnoid hemorrhage: a systematic review. *World Neurosurg* 85:305–314. <https://doi.org/10.1016/j.wneu.2015.08.054>
92. Marik PE, Cavallazzi R (2013) Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. *Crit Care Med* 41:1774–1781
93. Marik PE, Baram M, Vahid B (2008) Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. *Chest* 134:172–178. <https://doi.org/10.1378/chest.07-2331>
94. Mistry AM, Mistry EA, Ganesh Kumar N, Froehler MT, Fusco MR, Chitale RV (2016) Corticosteroids in the management of hyponatremia, hypovolemia, and vasospasm in subarachnoid hemorrhage: a meta-analysis. *Cerebrovasc Dis* 42:263–271. <https://doi.org/10.1159/000446251>
95. Moro N, Katayama Y, Igarashi T, Mori T, Kawamata T, Kojima J (2007) Hyponatremia in patients with traumatic brain injury: incidence, mechanism, and response to sodium supplementation or retention therapy with hydrocortisone. *Surg Neurol* 68:387–393. <https://doi.org/10.1016/j.surneu.2006.11.052>
96. Musch W, Thimpont J, Vandervelde D, Verhaeverbeke I, Berghmans T, Decaux G (1995) Combined fractional excretion of sodium and urea better predicts response to saline in hyponatremia than do usual clinical and biochemical parameters. *Am J Med* 99:348–355. [https://doi.org/10.1016/s0002-9343\(99\)80180-6](https://doi.org/10.1016/s0002-9343(99)80180-6)
97. Musch W, Hedeshi A, Decaux G (2004) Low sodium excretion in SIADH patients with low diuresis. *Nephron Physiol* 96:P11–P18. <https://doi.org/10.1159/000075575>
98. Nelson PB, Seif SM, Maroon JC, Robinson AG (1981) Hyponatremia in intracranial disease: perhaps not the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). *J Neurosurg* 55:938–941. <https://doi.org/10.3171/jns.1981.55.6.0938>
99. Nemergut EC, Zuo Z, Jane JA, Laws ER (2005) Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. *J Neurosurg* 103:448–454. <https://doi.org/10.3171/jns.2005.103.3.0448>
100. Nguyen MK, Kurtz I (2004) Determinants of plasma water sodium concentration as reflected in the Edelman equation: role of osmotic and Gibbs-Donnan equilibrium. *Am J Physiol Ren Physiol* 286:F828–F837. <https://doi.org/10.1152/ajprenal.00393.2003>
101. Nguyen MK, Kurtz I (2005) Derivation of a new formula for calculating urinary electrolyte-free water clearance based on the Edelman equation. *Am J Physiol Ren Physiol* 288:F1–F7. <https://doi.org/10.1152/ajprenal.00259.2004>
102. Palevsky PM, Bhargava R, Greenberg A (1996) Hyponatremia in hospitalized patients. *Ann Intern Med* 124:197–203
103. Palmer BF (2000) Hyponatremia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting. *Nephrol Dial Transplant* 15:262–268
104. Parenti G, Cecchi PC, Raggianti B, Schwarz A, Ammannati F, Mennona P, Di Rita A, Gallina P, Di Lorenzo N, Innocenti P, Forti G, Peri A (2011) Evaluation of the anterior pituitary function in the acute phase after spontaneous subarachnoid hemorrhage. *J Endocrinol Investig* 34:361–365. <https://doi.org/10.1007/BF03347460>
105. Prete A, Corsello SM, Salvatori R (2017) Current best practice in the management of patients after pituitary surgery. *Ther Adv Endocrinol* 8:33–48. <https://doi.org/10.1177/2042018816687240>
106. Qureshi AI, Suri MFK, Sung GY, Straw RN, Yahia AM, Saad M, Guterman LR, Hopkins LN (2002) Prognostic significance of hyponatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage. *Clin Neurosurg* 50:749–755 discussion 755–6
107. Rahman M, Friedman WA (2009) Hyponatremia in neurosurgical patients: clinical guidelines development. *Neurosurgery* 65:925–935. discussion 935–6. <https://doi.org/10.1227/01.NEU.0000358954.62182.B3>
108. Rajagopal R, Swaminathan G, Nair S, Joseph M (2017) Hyponatremia in traumatic brain injury: a practical management protocol. *World Neurosurg* 108:529–533. <https://doi.org/10.1016/j.wneu.2017.09.013>
109. Robertson GL, Shelton RL, Athar S (1976) The osmoregulation of vasopressin. *Kidney Int* 10:25–37. <https://doi.org/10.1038/ki.1976.76>
110. Robertson GL, Aycinena P, Zerbe RL (1982) Neurogenic disorders of osmoregulation. *Am J Med* 72:339–353. [https://doi.org/10.1016/0002-9343\(82\)90825-7](https://doi.org/10.1016/0002-9343(82)90825-7)

111. Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U (2010) Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. *Am J Kidney Dis* 56:325–337. <https://doi.org/10.1053/j.ajkd.2010.01.013>
112. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG (2005) Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. *Liver Transpl* 11:336–343. <https://doi.org/10.1002/lt.20329>
113. Sane T, Rantakari K, Poranen A, Tahtela R, Valimaki M, Pelkonen R (1994) Hyponatremia after transsphenoidal surgery for pituitary tumors. *J Clin Endocrinol Metab* 79:1395–1398. <https://doi.org/10.1210/jcem.79.5.7962334>
114. Sata A, Hizuka N, Kawamata T, Hori T, Takano K (2006) Hyponatremia after transsphenoidal surgery for hypothalamo-pituitary tumors. *Neuroendocrinology* 83:117–122. <https://doi.org/10.1159/000094725>
115. Sayama T, Inamura T, Matsushima T, Inoha S, Inoue T, Fukui M (2000) High incidence of hyponatremia in patients with ruptured anterior communicating artery aneurysms. *Neurol Res* 22:151–155
116. Schreckinger M, Walker B, Knepper J, Homyak M, Hong D, Kim J-M, Folbe A, Guthikonda M, Mittal S, Szerlip NJ (2013) Post-operative diabetes insipidus after endoscopic transsphenoidal surgery. *Pituitary* 16:445–451. <https://doi.org/10.1007/s11102-012-0453-1>
117. Schrier RW, Berl T, Anderson RJ (1979) Osmotic and nonosmotic control of vasopressin release. *Am J Phys* 236:F321–F332. <https://doi.org/10.1152/ajprenal.1979.236.4.F321>
118. Se I, Fukagawa A, Higashiyama M, Nakamura T, Kusaka I, Nagasaka S, Honda K, Saito T (2001) Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. *J Clin Endocrinol Metab* 86:1665–1671. <https://doi.org/10.1210/jcem.86.4.7426>
119. See AP, Wu KC, Lai PMR, Gross BA, Du R (2016) Risk factors for hyponatremia in aneurysmal subarachnoid hemorrhage. *J Clin Neurosci* 32:115–118. <https://doi.org/10.1016/j.jocn.2016.04.006>
120. Shah K, Turgeon RD, Gooderham PA, Ensom MHH (2018) Prevention and treatment of hyponatremia in patients with subarachnoid hemorrhage: a systematic review. *World Neurosurg* 109:222–229. <https://doi.org/10.1016/j.wneu.2017.09.182>
121. Sheehan JM, Sheehan JP, Douds GL, Page RB (2006) DDAVP use in patients undergoing transsphenoidal surgery for pituitary adenomas. *Acta Neurochir* 148:287–291. discussion 291. <https://doi.org/10.1007/s00701-005-0686-0>
122. Sherlock M, O'Sullivan E, Agha A, Behan LA, Rawluk D, Brennan P, Tormey W, Thompson CJ (2006) The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. *Clin Endocrinol* 64:250–254. <https://doi.org/10.1111/j.1365-2265.2006.02432.x>
123. Sivakumar V, Rajshekhar V, Chandy MJ (1994) Management of neurosurgical patients with hyponatremia and natriuresis. *Neurosurgery* 34:269–274— discussion 274. <https://doi.org/10.1227/00006123-199402000-00010>
124. Smith D, McKenna K, Moore K, Tormey W, Finucane J, Phillips J, Baylis P, Thompson CJ (2002) Baroregulation of vasopressin release in adipsic diabetes insipidus. *J Clin Endocrinol Metab* 87:4564–4568. <https://doi.org/10.1210/jc.2002-020090>
125. Spasowski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoom EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E (2014) Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Eur J Endocrinol* 170:G1–G47. <https://doi.org/10.1530/EJE-13-1020>
126. Staiger RD, Samthein J, Wiesli P, Schmid C, Bernays RL (2013) Prognostic factors for impaired plasma sodium homeostasis after transsphenoidal surgery. *Br J Neurosurg* 27:63–68. <https://doi.org/10.3109/02688697.2012.714013>
127. Sterns RH (2019) Evidence for managing hyponatremia: is it just hyponatremia in reverse? *Clin J Am Soc Nephrol* 14:645–647. <https://doi.org/10.2215/CJN.02950319>
128. Sterns RH, Nigwekar SU, Hix JK (2009) The treatment of hyponatremia. *Semin Nephrol* 29:282–299. <https://doi.org/10.1016/j.semnephrol.2009.03.002>
129. Story DA, Morimatsu H, Egi M, Bellomo R (2007) The effect of albumin concentration on plasma sodium and chloride measurements in critically ill patients. *Anesth Analg* 104:893–897. <https://doi.org/10.1213/01.ane.0000258015.87381.61>
130. Svirgi GE, Shik V, Raz B, Soustiel JF (2003) Role of brain natriuretic peptide in cerebral vasospasm. *Acta Neurochir* 145:851–860. discussion 860. <https://doi.org/10.1007/s00701-003-0101-7>
131. Takaku A, Shindo K, Tanaka S, Mori T, Suzuki J (1979) Fluid and electrolyte disturbances in patients with intracranial aneurysms. *Surg Neurol* 11:349–356
132. Thompson CJ, Selby P, Baylis PH (1991) Reproducibility of osmotic and nonosmotic tests of vasopressin secretion in men. *Am J Physiol Regul Integr Comp Physiol* 260:R533–R539. <https://doi.org/10.1152/ajpregu.1991.260.3.R533>
133. Thrasher TN, Keil LC, Ramsay DJ (1982) Lesions of the organum vasculosum of the lamina terminalis (OVLT) attenuate osmotically-induced drinking and vasopressin secretion in the dog. *Endocrinology* 110:1837–1839. <https://doi.org/10.1210/endo-110-5-1837>
134. Tomida M, Muraki M, Uemura K, Yamasaki K (1998) Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage. *Stroke* 29:1584–1587. <https://doi.org/10.1161/01.str.29.8.1584>
135. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S (1994) Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. *Epilepsia* 35:181–188. <https://doi.org/10.1111/j.1528-1157.1994.tb02930.x>
136. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ (2013) Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. In: *Am. J. Med.* pp. S1–42
137. Wang N, Nguyen PK, Pham CU, Smith EA, Kim B, Goetz MB, Graber CJ (2019) Sodium content of intravenous antibiotic preparations. *Open Forum Infect Dis* 6
138. Wartenberg KE, Schmidt JM, Claassen J, Temes RE, Frontera JA, Ostapovich N, Parra A, Connolly ES, Mayer SA (2006) Impact of medical complications on outcome after subarachnoid hemorrhage. *Crit Care Med* 34:617–623— quiz 624. <https://doi.org/10.1097/01.ccm.0000201903.46435.35>
139. Wijdicks EF, Vermeulen M, Haaf ten JA, Hijdra A, Bakker WH, van Gijn J (1985) Volume depletion and natriuresis in patients with a ruptured intracranial aneurysm. *Ann Neurol* 18:211–216. doi: <https://doi.org/10.1002/ana.410180208>
140. Wijdicks EF, Vermeulen M, Hijdra A, van Gijn J (1985) Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: is fluid restriction harmful? *Ann Neurol* 17:137–140. <https://doi.org/10.1002/ana.410170206>
141. Yuen KCJ, Ajmal A, Correa R, Little AS (2019) Sodium perturbations after pituitary surgery. *Neurosurg Clin N Am* 30:515–524. <https://doi.org/10.1016/j.nec.2019.05.011>
142. Zerbe RL, Miller JZ, Robertson GL (1991) The reproducibility and heritability of individual differences in osmoregulatory function in normal human subjects. *J Lab Clin Med* 117:51–59

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.